What is Thymalin?
Thymalin is a peptide mixture extracted from calf thymus, the gland where immune T cells mature, that has been registered as an immunomodulating (immune adjusting) drug in Russia since the 1980s. The developer's 2003 trial in elderly people, which the paper describes as randomized (assigned by chance) and placebo controlled, reported lower eight-year mortality with Thymalin than with placebo, but its methods are sparsely reported, it comes from the developing institute, and it has never been independently replicated. It has never been reviewed or approved by FDA, is not on the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), and is not available through licensed channels in the United States.
Thymalin is a polypeptide extract from calf thymus (a mixture of low molecular weight peptides), registered as a drug in Russia. It is also known as Thymalinum, Thymus extract peptide complex, Timalin, Glu-Trp dipeptide (thymogen) is its synthetic derivative.
How does it work?
Thymalin contains short thymic peptides, including the dipeptide Glu-Trp, that are proposed to promote differentiation and maturation of T lymphocytes and to normalize the ratio of helper to suppressor T cells. In vitro, thymalin activated differentiation of human hematopoietic stem cells and altered expression of genes involved in immune signaling in cell lines. Mechanisms come from cell studies and Russian clinical reports rather than dedicated human pharmacology studies.
| Cluster | Longevity and mitochondrial |
|---|---|
| Routes | Intramuscular injection (Russian labeling and reports); Subcutaneous injection (as sold) |
| Conditions studied | Inflammation and inflammatory bowel disease; Longevity and healthy aging; Immune support and immune deficiency |
| Record | v4, reviewed, verified Sep 30, 2026 |
What does the evidence say about Thymalin?
The deciding study is Khavinson and Morozov 2003 (PMID 14523363), which PubMed tags as a randomized controlled trial. Its full text describes 152 elderly people divided by stratified randomization into placebo (48), Thymalin (58), or pineal extract Epithalamin (46) groups and given six courses over 3 years; eight-year mortality was 13.6% with placebo, 6.6% with Thymalin, and 8.5% with Epithalamin, and a second arm of 94 women is described as double blind. Reporting is sparse, the trial comes from the developing institute, and it has never been independently replicated, so the grade describes how the evidence was gathered, not how well thymalin works. A 2021 report added thymalin to standard COVID-19 care and described a faster fall in inflammatory markers; its abstract does not state the sample size or how patients were assigned.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 1 | 266 |
| Human observational studies | 1 | n/a |
| Animal studies | 1 | n/a |
| All indexed studies | 3 | 266 |
Human evidence
Khavinson 2003: PubMed tags this as a randomized controlled trial, and the abstract reports 266 elderly people followed for 6 to 8 years, with the preparations given during the first 2 to 3 years. The full text describes 152 people divided into 3 groups by stratified randomization to placebo (48), Thymalin (58), or Epithalamin (46), six courses over 3 years, with eight-year mortality of 13.6%, 6.6%, and 8.5% respectively, and a second arm of 94 women described as double blind. The authors also report a 2.0 to 2.4 fold lower incidence of acute respiratory disease. Reporting is sparse, the work comes from the developing institute, and it has never been independently replicated. Khavinson 2021: thymalin added to standard therapy in COVID-19 patients, reporting a faster decline in IL-6, C-reactive protein, and D-dimer than standard therapy alone; the abstract does not state the sample size, randomization, or blinding. No pharmacokinetic or dose ranging study has been published in English.
Animal evidence
Rodent and cell studies from the same group report restoration of immune function after thymectomy, radiation, or aging and stimulation of T cell differentiation. Khavinson 2020 showed thymalin activated differentiation of human hematopoietic stem cells in culture. Independent animal work is scarce.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Peptides of pineal gland and thymus prolong human life2003 PMID 14523363 | Randomized, placebo controlled trial (PubMed publication type: randomized controlled trial); the full text describes stratified randomization into 3 groups and a second arm described as double blind; sparsely reportedn = 266 Elderly people in St. Petersburg and Kiev: the abstract reports 266 people followed for 6 to 8 years; the full text describes 152 people randomized to placebo (48), Thymalin (58), or Epithalamin (46), plus a second arm of 94 women | Eight-year mortality 13.6% with placebo, 6.6% with Thymalin, and 8.5% with Epithalamin; the abstract reports 2.0 to 2.1 fold lower mortality with Thymalin and a 2.0 to 2.4 fold lower incidence of acute respiratory disease; from the developing institute and never independently replicated | Evidence: Human RCT evidence |
| Thymalin: activation of differentiation of human hematopoietic stem cells2020 PMID 33237528 | In vitro studyCultured human hematopoietic stem cells | Thymalin increased expression of differentiation markers in cultured hematopoietic stem cells | Evidence: Animal-only evidence |
| Results and prospects of using activator of hematopoietic stem cell differentiation in complex therapy for patients with COVID-192021 PMID 33575961 | Clinical comparison of standard therapy with and without thymalin; assignment method and blinding not stated in the abstractPatients with COVID-19 receiving standard therapy with or without thymalin; sample size not stated in the abstract | Adding thymalin to standard therapy accelerated the decline in IL-6, C-reactive protein, and D-dimer | Evidence: Human observational evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Inflammation and inflammatory bowel disease | Not graded | KPV, thymosin alpha-1, LL-37, VIP, and BPC-157 are marketed as anti-inflammatory peptides. Thymosin alpha-1 has human trials in hepatitis and sepsis outside the United States. KPV has rodent colitis data only. VIP analogs have been studied in small human trials for sarcoidosis and pulmonary hypertension. |
| Longevity and healthy aging | Not graded | No peptide has been shown to extend human lifespan. MOTS-c, humanin, and SS-31 (elamipretide) are mitochondrial peptides with rodent data and, for elamipretide, human trials in mitochondrial myopathy and Barth syndrome. Epitalon and FOXO4-DRI rest on animal or in vitro data; epitalon's two indexed human studies measured melatonin, not telomere length or life span. GLP-1 agonists have the strongest human outcome data for mortality relevant endpoints, through cardiovascular risk reduction. |
| Immune support and immune deficiency | Evidence: Human RCT evidence | One sparsely reported randomized, placebo-controlled trial in elderly people, from the institute that developed it and never independently replicated, reported lower mortality and fewer acute respiratory illnesses; a 2021 COVID-19 report described a faster fall in inflammatory markers without stating sample size or how patients were assigned; not approved outside Russia. |
Is Thymalin legal in the United States?
FDA and compounding status
Thymalin is not an FDA approved drug and PeptideAgent has not identified it on the FDA 503A bulks nomination lists or in any Pharmacy Compounding Advisory Committee review. As an animal tissue extract of undefined composition it is not a candidate for 503A bulk compounding, and it is not eligible for 503B outsourcing. It is registered as a prescription drug in Russia and some neighboring countries. Products sold in the United States under this name for human use are unapproved drugs.
WADA status
WADA status unclear. The current prohibited list does not name this compound explicitly and its class status is not settled. Athletes should ask their anti-doping organization before use.
Regulatory timeline
No regulatory events recorded.
Full tracker for Thymalin or the category-wide tracker.
Email me when Thymalin's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of Thymalin used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Not established in indexed human literature. Russian labeling describes intramuscular courses, but no dose finding trial has been published in an indexed journal, so no dose range is reported here.
Routes reported
| # | Route |
|---|---|
| 1 | Intramuscular injection (Russian labeling and reports) |
| 2 | Subcutaneous injection (as sold) |
What are the side effects and interactions of Thymalin?
Side effects
| # | Reported side effect |
|---|---|
| 1 | No systematic safety data have been published |
| 2 | Allergic reactions are the main risk listed for a bovine tissue extract |
| 3 | Injection site pain |
| 4 | Theoretical prion and adventitious agent risk with unverified bovine thymus products of unknown origin |
Interactions
| # | Interaction |
|---|---|
| 1 | No formal interaction studies exist |
| 2 | Theoretical opposition to immunosuppressants (corticosteroids, calcineurin inhibitors, biologics) given proposed immune stimulating action (not tested) |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Known hypersensitivity to bovine proteins |
| 2 | Autoimmune disease or organ transplant (theoretical immune stimulation) |
| 3 | Pregnancy and breastfeeding (no data) |
| 4 | Competitive athletes should confirm status with their anti-doping organization |
How do people access Thymalin legally?
Typical cost: Not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Access options
Not available
Not legally available in the United States: no approved product and no 503A bulks listing.
Outside the US
Prescription drug in Russia and some neighboring countries.
Not available
Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare Thymalin
What's actually offered, and what that means for you
FDA has found an online seller offering thymalin anyway. [8]
Being offered does not change the legal status of thymalin. Thymalin is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [4] [9]
What FDA found
- February 2024: FDA found an online seller offering thymalin with immune and heart claims, including for children, and called it an unapproved new drug despite research-chemical disclaimers. [8]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [9] [10] [11] [12] [13] [14]
What that means for you
- A pharmacy that compounds thymalin is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [10] [11]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [14]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [15]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [16] [17]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [9]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, WADA status is unclear; ask your anti-doping organization before any use. [6]
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound thymalin, with or without a prescription. [4]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [18] [19] [20]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [20] [21] [22]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [14] [23] [24] [25] [26] [27]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [14]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [18]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [22]
- Pharmacy: Is this made for me on a prescription written in my name? [21]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [20] [22]
- Prescriber: What is the legal basis for a pharmacy to compound thymalin? Is it FDA approved or on the 503A bulks list? [4] [14]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [22]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [15]
Frequently asked questions
Is thymalin legal in the United States?
It is not an FDA approved drug and is not on the FDA 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), so no US compounding pharmacy can lawfully make it. Possessing it is not a crime, but selling it for human use is unlawful: the only products on the US market are research chemicals, which are unapproved drugs. It is a registered prescription drug in Russia. [4] [5] [7]
Does thymalin work to boost the immune system?
The main human study is a 2003 trial from the developing institute that its paper describes as randomized and placebo controlled; it reported improved immune indices, fewer acute respiratory infections, and lower mortality in elderly people given Thymalin. An in vitro study showed thymalin activated differentiation of human blood stem cells. The trial's methods are sparsely reported and it has never been independently replicated, so the effect size in people is unknown. PeptideAgent grades the evidence human RCT because a randomized trial is indexed; the grade describes how the evidence was gathered, not how well thymalin works. [1] [2] [3]
Does thymalin extend lifespan?
The claim comes from a 2003 trial in which elderly people randomized to Thymalin courses had lower eight-year mortality than those given placebo (6.6% versus 13.6%). The paper describes stratified randomization and a placebo group, but its methods are sparsely reported, it comes from the institute that developed the drug, and it has never been replicated independently, so on its own it does not establish that thymalin prolongs life. [1]
What are the side effects of thymalin?
No systematic safety data have been published. As a bovine thymus extract, allergic reactions are the main labeled risk, along with injection site pain. Unverified products carry the additional concern of contamination or animal derived infectious agents, since the source and processing cannot be checked. [3]
How is thymalin taken?
Not established in indexed human literature. Russian labeling describes intramuscular courses given as short repeated cycles, but no dose finding trial has been published in an indexed journal, so PeptideAgent does not report a regimen. [1] [3]
Is thymalin banned by WADA?
Unclear. Thymalin is not named on the WADA Prohibited List, and because it is an approved drug in Russia it does not fall automatically under section S0 for non-approved substances. However, its composition is undefined and immune modulators can be reviewed case by case, so athletes should check with their anti-doping organization before use. [6]
Thymalin vs thymosin alpha-1: what is the difference?
Thymosin alpha-1 is a single defined 28 amino acid peptide that has been approved in several countries and studied in randomized trials for hepatitis B and as a vaccine adjuvant. Thymalin is an undefined mixture of thymus peptides whose one randomized trial comes from its developer, is sparsely reported, and has never been replicated. Neither is FDA approved, but thymosin alpha-1 has a far larger and more rigorous evidence base. [1] [2]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
From the blog
- Thymosin alpha-1 access: approved abroad, not in the US
Thymosin alpha-1 is approved as Zadaxin in more than 30 countries but has never been FDA approved, and it is not on the 503A bulks list. What that means for access, forms, and thymalin.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003PubMed 14523363, 2003
- [2]Khavinson VK et al. Thymalin: activation of differentiation of human hematopoietic stem cells. Bull Exp Biol Med 2020PubMed 33237528, 2020
- [3]Khavinson VK et al. Results and prospects of using activator of hematopoietic stem cell differentiation in complex therapy for patients with COVID-19. Stem Cell Rev Rep 2021PubMed 33575961, 2021
- [4]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [5]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [6]WADA Prohibited ListWADA, 2026
- [7]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [8]FDA warning letter 669074, February 7, 2024, to an online seller of research-use-only chemicals (FDA warning letters database)FDA, 2024
- [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2)FDA
- [10]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 30). Thymalin: evidence, legality, and access. https://peptideagent.ai/peptides/thymalin- HTML link
<a href="https://peptideagent.ai/peptides/thymalin">Thymalin: evidence, legality, and access</a>, PeptideAgent, updated September 30, 2026.